Recent Patents on Anti-Cancer Potential of Helenalin.
Activities
Arnica
anti-cancer
helenalin
patents
synthetic derivatives
Journal
Recent patents on anti-cancer drug discovery
ISSN: 2212-3970
Titre abrégé: Recent Pat Anticancer Drug Discov
Pays: United Arab Emirates
ID NLM: 101266081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
11
12
2019
revised:
08
05
2020
accepted:
15
05
2020
pubmed:
3
7
2020
medline:
27
7
2021
entrez:
3
7
2020
Statut:
ppublish
Résumé
Arnica montana, containing helenalin as its principal active constituent, is the most widely used plant to treat various ailments. Recent studies indicate that Arnica and helenalin provide significant health benefits, including anti-inflammatory, neuroprotective, antioxidant, cholesterol-lowering, immunomodulatory, and most important, anti-cancer properties. The objective of the present study is to overview the recent patents of Arnica and its principal constituent helenalin, including new methods of isolation, and their use in the prevention of cancer and other ailments. Current prose and patents emphasizing the anti-cancer potential of helenalin and Arnica, incorporated as anti-inflammary agents in anti-cancer preparations, have been identified and reviewed with particular emphasis on their scientific impact and novelty. Helenalin has shown its anti-cancer potential to treat multiple types of tumors, both in vitro and in vivo. It has also portrayed synergistic effects when given in combination with other anti- cancer drugs or natural compounds. New purification/isolation techniques are also developing with novel helenalin formulations and its synthetic derivatives have been developed to increase its solubility and bioavailability. The promising anti-cancer potential of helenalin in various preclinical studies may open new avenues for therapeutic interventions in different tumors. Thus clinical trials validating its tumor suppressing and chemopreventive activities, particularly in conjunction with standard therapies, are immediately required.
Sections du résumé
BACKGROUND
BACKGROUND
Arnica montana, containing helenalin as its principal active constituent, is the most widely used plant to treat various ailments. Recent studies indicate that Arnica and helenalin provide significant health benefits, including anti-inflammatory, neuroprotective, antioxidant, cholesterol-lowering, immunomodulatory, and most important, anti-cancer properties.
OBJECTIVE
OBJECTIVE
The objective of the present study is to overview the recent patents of Arnica and its principal constituent helenalin, including new methods of isolation, and their use in the prevention of cancer and other ailments.
METHODS
METHODS
Current prose and patents emphasizing the anti-cancer potential of helenalin and Arnica, incorporated as anti-inflammary agents in anti-cancer preparations, have been identified and reviewed with particular emphasis on their scientific impact and novelty.
RESULTS
RESULTS
Helenalin has shown its anti-cancer potential to treat multiple types of tumors, both in vitro and in vivo. It has also portrayed synergistic effects when given in combination with other anti- cancer drugs or natural compounds. New purification/isolation techniques are also developing with novel helenalin formulations and its synthetic derivatives have been developed to increase its solubility and bioavailability.
CONCLUSION
CONCLUSIONS
The promising anti-cancer potential of helenalin in various preclinical studies may open new avenues for therapeutic interventions in different tumors. Thus clinical trials validating its tumor suppressing and chemopreventive activities, particularly in conjunction with standard therapies, are immediately required.
Identifiants
pubmed: 32614752
pii: PRA-EPUB-107856
doi: 10.2174/1574892815666200702142601
doi:
Substances chimiques
Antineoplastic Agents, Phytogenic
0
Sesquiterpenes, Guaiane
0
helenalin
4GUY9L896T
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
132-142Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.